Tagrisso medication contains an active substance called Osimertinib that belongs to the anti-cancer class of medications known as a protein kinase inhibitor. This substance blocks the mutated receptor in patients who have a T790M mutation to further inhibit tumour growth. The branded medication Tagrisso is manufactured by AstraZeneca and approved in over 70 countries including USA, UK, China and Japan. This medication is often prescribed for the treatment of EGFR T790M mutation positive non-small cell lung cancer.
